Oculis   Report issue

For profit Phase 2 Phase 3
Founded: Lausanne Switzerland (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2019
NCT04130802
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Oculis